Cargando…
High dupilumab levels in tear fluid of atopic dermatitis patients with moderate‐to‐severe ocular surface disease
BACKGROUND: The patho‐mechanism of ocular surface disease (OSD) in dupilumab‐treated atopic dermatitis (AD) patients remains unclear. The aim of this study is to measure dupilumab levels in tear fluid and serum, and relate these findings to the severity of OSD during dupilumab treatment in AD patien...
Autores principales: | Achten, Roselie, Thijs, Judith, van der Wal, Marlot, van Luijk, Chantal, van Luin, Matthijs, el Amrani, Mohsin, Knol, Edward, Delemarre, Eveline, Jager, Constance den Hartog, de Graaf, Marlies, Bakker, Daphne, de Boer, Joke, van Wijk, Femke, de Bruin‐Weller, Marjolein |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9842774/ https://www.ncbi.nlm.nih.gov/pubmed/36705509 http://dx.doi.org/10.1002/clt2.12221 |
Ejemplares similares
-
Ocular surface disease is common in moderate‐to‐severe atopic dermatitis patients
por: Achten, Roselie E., et al.
Publicado: (2022) -
Identification of Risk Factors for Dupilumab-associated Ocular Surface Disease in Patients with Atopic Dermatitis
por: ACHTEN, Roselie E., et al.
Publicado: (2022) -
Conjunctival inflammation in dupilumab‐treated atopic dermatitis comprises a multicellular infiltrate with elevated T1/T17 cytokines: A case series study
por: Bakker, Daphne S., et al.
Publicado: (2021) -
Economic and Humanistic Burden in Paediatric Patients with Atopic Dermatitis
por: ACHTEN, Roselie, et al.
Publicado: (2023) -
Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis
por: Bakker, D.S., et al.
Publicado: (2019)